CRDF · NASDAQ
Cardiff Oncology (CRDF) Stock Price & Fundamentals
Cardiff Oncology (CRDF) closed at $441.41 on Oct 9, 2026, down 1.11% from the previous close of $446.37.
Share price, past year
1Y +21.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $441.41 |
| Sep 30, 2026 | $440.39 |
| Aug 31, 2026 | $444.11 |
| Jul 31, 2026 | $444.97 |
| Jun 30, 2026 | $438.65 |
| May 29, 2026 | $432.02 |
| Apr 30, 2026 | $409.87 |
| Mar 31, 2026 | $391.49 |
| Feb 27, 2026 | $396.26 |
| Jan 30, 2026 | $382.79 |
| Dec 31, 2025 | $357.90 |
| Nov 28, 2025 | $349.40 |
| Oct 31, 2025 | $351.69 |
Key statistics
- Market cap
- $30.24B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.60
- Revenue (TTM)
- $508.00K
- Net income (TTM)
- −$40.05M
- Shares outstanding
- 68.5M
- Dividend yield
- —
- 52-week range
- $340.84 – $470.02
Cardiff Oncology's market cap is $30.24B, based on a share price of $441.41 and 68.5M shares outstanding as of Jun 30, 2026.
Financials
Cardiff Oncology reported revenue of $593.00K for fiscal 2025, down 13.18% from fiscal 2024.
Cardiff Oncology reported a net loss of $45.85M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $593.00K | −13.2% | −$45.85M | −7,732.0% | −$0.69 | −$37.97M |
| FY2024ended Dec 31, 2024 | $683.00K | +40.0% | −$45.43M | −6,651.7% | −$0.95 | −$37.77M |
| FY2023ended Dec 31, 2023 | $488.00K | +26.4% | −$41.44M | −8,492.0% | −$0.93 | −$31.47M |
| FY2022ended Dec 31, 2022 | $386.00K | +7.5% | −$38.70M | −10,026.9% | −$0.89 | −$34.83M |
| FY2021ended Dec 31, 2021 | $359.00K | −1.9% | −$28.29M | −7,880.5% | −$0.73 | −$23.25M |
| FY2020ended Dec 31, 2020 | $365.99K | +49.6% | −$19.31M | −5,275.2% | −$1.08 | −$16.53M |
| FY2019ended Dec 31, 2019 | $244.63K | −35.3% | −$16.41M | −6,709.7% | −$2.80 | −$13.34M |
| FY2018ended Dec 31, 2018 | $378.33K | −25.1% | −$16.46M | −4,351.1% | −$49.55 | −$13.20M |
| FY2017ended Dec 31, 2017 | $505.40K | +32.6% | −$24.91M | −4,928.1% | −$310.50 | — |
| FY2016ended Dec 31, 2016 | $381.07K | — | −$39.20M | −10,287.8% | −$8.22 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $104.00K | −$9.23M | −$0.14 |
| Q1 FY2026ended Mar 31, 2026 | $41.00K | −$12.35M | −$0.18 |
| Q4 FY2025ended Dec 31, 2025 | $243.00K | −$7.22M | −$0.11 |
| Q3 FY2025ended Sep 30, 2025 | $120.00K | −$11.26M | −$0.17 |
| Q2 FY2025ended Jun 30, 2025 | $121.00K | −$13.94M | −$0.21 |
| Q1 FY2025ended Mar 31, 2025 | $109.00K | −$13.43M | −$0.20 |
| Q4 FY2024ended Dec 31, 2024 | $150.00K | −$11.79M | −$0.22 |
| Q3 FY2024ended Sep 30, 2024 | $165.00K | −$11.86M | −$0.25 |
Company profile
- Name
- Cardiff Oncology, Inc.
- Ticker
- CRDF
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 11055 Flintkote Avenue, San Diego, CA 92121
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001213037
Recent SEC filings
- Sep 14, 2026
- Aug 11, 2026
- Aug 11, 2026
- Jul 16, 2026
- Jun 11, 2026
- Jun 3, 2026
- May 29, 2026
- May 19, 2026
Frequently asked questions
What is Cardiff Oncology's stock price?
Cardiff Oncology (CRDF) closed at $441.41 on Oct 9, 2026, down 1.11% from the previous close of $446.37.
What is Cardiff Oncology's market cap?
Cardiff Oncology's market cap is $30.24B, based on a share price of $441.41 and 68.5M shares outstanding as of Jun 30, 2026.
How much revenue does Cardiff Oncology make?
Cardiff Oncology reported revenue of $593.00K for fiscal 2025, down 13.18% from fiscal 2024.
Does Cardiff Oncology pay a dividend?
Cardiff Oncology's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Cardiff Oncology, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures